Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality

Philippe Prouet, Smith Giri, Eric Wiedower, Andrew Fintel, George Yaghmour, Elena Paulus Lamb, Jeremiah Deneve, Martin Fleming, Paxton Dickson, Jason C. Chandler, Michael Martin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of-8.9% (95% confidence interval=-9.7% to-8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.

Original languageEnglish (US)
Pages (from-to)813-818
Number of pages6
JournalAnticancer Research
Volume37
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Stomach
Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Mortality
Epidemiology
Drug Approval
Rituximab
Databases
Confidence Intervals
Food
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality. / Prouet, Philippe; Giri, Smith; Wiedower, Eric; Fintel, Andrew; Yaghmour, George; Lamb, Elena Paulus; Deneve, Jeremiah; Fleming, Martin; Dickson, Paxton; Chandler, Jason C.; Martin, Michael.

In: Anticancer Research, Vol. 37, No. 2, 2017, p. 813-818.

Research output: Contribution to journalArticle

Prouet, Philippe ; Giri, Smith ; Wiedower, Eric ; Fintel, Andrew ; Yaghmour, George ; Lamb, Elena Paulus ; Deneve, Jeremiah ; Fleming, Martin ; Dickson, Paxton ; Chandler, Jason C. ; Martin, Michael. / Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality. In: Anticancer Research. 2017 ; Vol. 37, No. 2. pp. 813-818.
@article{ae3ead75558140d4ac4a71bec54f8eda,
title = "Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality",
abstract = "Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4{\%} in 1983 to 6.9{\%} in 2012, with an annual percentage change of-8.9{\%} (95{\%} confidence interval=-9.7{\%} to-8.3{\%}; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.",
author = "Philippe Prouet and Smith Giri and Eric Wiedower and Andrew Fintel and George Yaghmour and Lamb, {Elena Paulus} and Jeremiah Deneve and Martin Fleming and Paxton Dickson and Chandler, {Jason C.} and Michael Martin",
year = "2017",
doi = "10.21873/anticanres.11382",
language = "English (US)",
volume = "37",
pages = "813--818",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality

AU - Prouet, Philippe

AU - Giri, Smith

AU - Wiedower, Eric

AU - Fintel, Andrew

AU - Yaghmour, George

AU - Lamb, Elena Paulus

AU - Deneve, Jeremiah

AU - Fleming, Martin

AU - Dickson, Paxton

AU - Chandler, Jason C.

AU - Martin, Michael

PY - 2017

Y1 - 2017

N2 - Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of-8.9% (95% confidence interval=-9.7% to-8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.

AB - Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of-8.9% (95% confidence interval=-9.7% to-8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.

UR - http://www.scopus.com/inward/record.url?scp=85013652110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013652110&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11382

DO - 10.21873/anticanres.11382

M3 - Article

VL - 37

SP - 813

EP - 818

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -